<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03291002</url>
  </required_header>
  <id_info>
    <org_study_id>CV-8102-008</org_study_id>
    <nct_id>NCT03291002</nct_id>
  </id_info>
  <brief_title>Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC</brief_title>
  <official_title>Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CureVac AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cromos Pharma LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CureVac AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates intratumoral administration of CV8102 in patients with advanced&#xD;
      melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck,&#xD;
      or adenoid cystic carcinoma.&#xD;
&#xD;
      Patients will receive CV8102 as single agent or in combination with SoC anti-PD-1 therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, cohort-based, dose escalation and expansion study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose determination for dose escalation cohorts</measure>
    <time_frame>2 weeks</time_frame>
    <description>Maximum tolerated dose (MTD) and recommended dose (RD), respectively, for CV8102 alone&#xD;
MTD and recommended combination dose (RCD) for CV8102 in combination with the standard dose of an anti-PD-1 antagonist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment related (Serious) Adverse Events (Tolerability and Safety profile)</measure>
    <time_frame>up to 12 months (end of study)</time_frame>
    <description>• Tolerability and safety profile of CV8102 alone and in combination with anti-PD-1 antagonists</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>up to 12 months (end of study)</time_frame>
    <description>• Anti-tumor activity of CV8102 per irRECIST and RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease status</measure>
    <time_frame>6 months</time_frame>
    <description>• Tumor Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>up to 12 months (end of study)</time_frame>
    <description>• Extent of tumor response at injected and non-injected lesions, if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 12 months (end of study)</time_frame>
    <description>• Survival time</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Melanoma (Skin)</condition>
  <condition>Squamous Cell Carcinoma of the Skin</condition>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Carcinoma, Adenoid Cystic</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of CV8102</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional expansion cohorts of CV8102</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of CV8102 + anti-PD-1 therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional expansion of CV8102 + anti-PD-1 therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CV8102</intervention_name>
    <description>CV8102 alone</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CV8102 + anti-PD-1 therapy</intervention_name>
    <description>CV8102 in combination with standard of care anti-PD-1 therapy</description>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Patients enrolled into Cohorts A and B (single agent CV8102) must have:&#xD;
&#xD;
               -  histologically confirmed advanced cutaneous melanoma, cutaneous squamous cell&#xD;
                  carcinoma, head and neck squamous cell carcinoma, or adenoid cystic carcinoma&#xD;
                  with documented disease progression&#xD;
&#xD;
               -  not amenable to surgical resection or locoregional radiation therapy with&#xD;
                  curative intent&#xD;
&#xD;
               -  at least 1 line of anti-cancer therapy for advanced disease (except adenoid&#xD;
                  cystic carcinoma) and documented Progression&#xD;
&#xD;
               -  cutaneous melanoma Cohort B3: Willing to undergo baseline and post-baseline&#xD;
                  biopsy of the lesion which is to be injected&#xD;
&#xD;
          2. Patients enrolled into Cohort C (CV8102 in combination with anti-PD-1 therapy) must&#xD;
             have&#xD;
&#xD;
               -  histologically confirmed advanced cMEL or hnSCC&#xD;
&#xD;
               -  indication for anti-PD-1 therapy or currently receiving anti-PD-1 therapy with&#xD;
                  stable of slowly progressing disease after at last 8 weeks (hnSCC) or 12 weeks&#xD;
                  (cMEL) of anti-PD-1 therapy prior to Day 1&#xD;
&#xD;
          3. Patients enrolled into Cohort D1 (CV8102 in combination with anti-PD-1 therapy) must&#xD;
             have&#xD;
&#xD;
               -  histologically confirmed advanced cMEL&#xD;
&#xD;
               -  either anti-PD-1 naive patients with indication for anti-PD-1 therapy (Cohort&#xD;
                  D1a) or patients refractory to anti-PD-1 therapy (Cohort D1b)&#xD;
&#xD;
               -  Presence of measurable lesion(s) according to RECIST 1.1, not intended for&#xD;
                  injection&#xD;
&#xD;
               -  Willing to undergo tumor biopsies at specific timepoints (Cohort D1a: baseline;&#xD;
                  Cohort D1b baseline and post-baseline biopsy of the injected lesion - only for&#xD;
                  selected sites)&#xD;
&#xD;
          4. Patients enrolled into Cohort D2 (CV8102 in combination with anti-PD-1 therapy) must&#xD;
             have&#xD;
&#xD;
               -  histologically confirmed advanced hnSCC&#xD;
&#xD;
               -  indication for treatment with first-line pembrolizumab (patients naive to&#xD;
                  anti-PD-1/anti-PD-L1)&#xD;
&#xD;
               -  PD-L1 combined positive score ≥ 1% according to local practice&#xD;
&#xD;
          5. Presence of at least one injectable tumor lesion that is measurable according to&#xD;
             RECIST 1.1&#xD;
&#xD;
          6. Recovered from prior toxicities to CTCAE grade ≤ 1 or grade ≤ 2&#xD;
&#xD;
          7. Resolution of CPI-related adverse effects, if applicable (including irAEs) back to&#xD;
             CTCAE grade 0/1&#xD;
&#xD;
          8. ECOG PS 0 or 1&#xD;
&#xD;
          9. 18 years of age or older&#xD;
&#xD;
         10. Adequate hematologic, renal, hepatic and coagulation function&#xD;
&#xD;
         11. Use of effective contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Rapidly progressing multi-focal metastatic or acutely life threatening disease&#xD;
&#xD;
          2. Prior use of topical/localTLR-7/8 agonists within the past 6 months&#xD;
&#xD;
          3. Clinically active central nervous system metastases and/or carcinomatous meningitis&#xD;
             (patients with stable brain metastases are eligible)&#xD;
&#xD;
          4. Ocular and mucosal melanoma&#xD;
&#xD;
          5. Prior anti-cancer therapy within specified time-periods depending on the indication&#xD;
&#xD;
          6. Tumor lesions that are to be injected close to major blood vessels or nerves, or whose&#xD;
             injection could potentially result in clinical adverse effects if post-treatment tumor&#xD;
             swelling or inflammation were to occur&#xD;
&#xD;
          7. Lesions that are to be injected in previously irradiated areas unless progressive&#xD;
             tumor growth has been demonstrated (no prior irradiation of injected lesions on&#xD;
             patients with melanoma)&#xD;
&#xD;
          8. History of active coagulation or bleeding disorder or need for ongoing therapeutic&#xD;
             anticoagulation that cannot be safely interrupted at th etime of IT injection or&#xD;
             biopsy du eto Underlying medical conditions; patients with melanoma and cutaneous&#xD;
             squamous cell carcinoma with controlled oral anticoagulation are eligible&#xD;
&#xD;
          9. Treatment with any investigational anticancer agent within 30 days or 5 half-lives&#xD;
             (whichever is longer) prior to the first dose of study drug or planned during the&#xD;
             study&#xD;
&#xD;
         10. Acute hypophysitis or endocrinopathies that are not adequately controlled by hormonal&#xD;
             replacement therapy or thyreostatic treatment&#xD;
&#xD;
         11. Use of immune modulating drugs or immunologically active topical therapies within 28&#xD;
             days of administration of the first dose of study drug&#xD;
&#xD;
         12. Chronic systemic immunosuppressive therapy including chronic corticosteroids within 28&#xD;
             days of the first dose of study drug (except physiological maintenance/replacement&#xD;
             steroid doses, topical steroids outside the injected lesion or inhaled steroids);&#xD;
             patients are eligible if steroid requirement is &lt; 10 mg/day of prednisone (or&#xD;
             equivalent) for at least 2 weeks&#xD;
&#xD;
         13. History of active autoimmune disease requiring immunosuppressive medication (except&#xD;
             Vitiligo and except CPI-mediated irAEs)&#xD;
&#xD;
         14. Known hematologic malignancy or malignant primary solid tumor that have occured or&#xD;
             reoccurred within the previous 5 years&#xD;
&#xD;
         15. Recent thromboembolic complications, or clinically significant cardiovascular disease,&#xD;
             or any other uncontrolled illness that would pose a risk to patient safety&#xD;
&#xD;
         16. Severe infection or acute inflammatory state&#xD;
&#xD;
         17. Seropositivity for human immunodeficiency virus (HIV), hepatitis B virus (HBV) surface&#xD;
             antigen (except in previously vaccinated patients) or hepatitis C virus (HCV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Eigentler, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>thomas.eigentler@charite.de</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Dermatologie der Paracelsus medizinischen Privatuniversität Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik III, Universitätsklinikum Bonn, Hämatologie, Immunonkologie und Rheumatologie</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elbe-Klinikum-Buxtehude, Hautkrebszentrum</name>
      <address>
        <city>Buxtehude</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen,Hautklinik, Internistisches Zentrum (INZ)</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Klinik für Dermatologie, Allergologie und Venerologie</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik Hornheide</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik für Hautkrankheiten, ZiD- Zentrum für innovative Dermatologie</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Hautklinik, Abtl. Dermatologische Onkologie</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Personalized Oncology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National Medical Research Center of Oncology n.a. N.N. Blokhin&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;National Medical Research Oncology Center n.a. N.N. Petrov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State University, Clinic of advanced medical technologies n. a. Nicolay I. Pirogov.</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals - Institut Catala dOncologia ICO</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqus de Valdecilla Santander</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

